相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU)
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
Shogo Kumagai et al.
CANCER CELL (2022)
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Luis G. Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
Pottayil G. Sasikumar et al.
FRONTIERS IN IMMUNOLOGY (2022)
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination
Ana Arance et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer
Minsuk Kwon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway
Qian Wu et al.
ACTA PHARMACOLOGICA SINICA (2021)
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
Pottayil G. Sasikumar et al.
COMMUNICATIONS BIOLOGY (2021)
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate O17 and O57: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer (vol 39, pg 723, 2021)
Borghaei
JOURNAL OF CLINICAL ONCOLOGY (2021)
Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation
Chenghao Pan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer
Hossein Borghaei et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Platinum Derivatives Effects on Anticancer Immune Response
Cedric Rebe et al.
BIOMOLECULES (2020)
KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression
Xiao Albert Zhou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Cisplatin: The first metal based anticancer drug
Sumit Ghosh
BIOORGANIC CHEMISTRY (2019)
CA-170-A Potent Small-Molecule PD-L1 Inhibitor or Not?
Bogdan Musielak et al.
MOLECULES (2019)
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways
Pottayil G. Sasikumar et al.
BIODRUGS (2018)
FBXO38 mediates PD-1 ubiquitination and regulates anti-tumour immunity of T cells
Xiangbo Meng et al.
NATURE (2018)
Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
David F. McDermott et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy
Hao-Nan Chang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Rafael Winograd et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum Complexes
Matthew D. Hall et al.
CANCER RESEARCH (2014)
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
Janis M. Taube et al.
CLINICAL CANCER RESEARCH (2014)
Cisplatin in cancer therapy: Molecular mechanisms of action
Shaloam Dasari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity
Elena Gianchecchi et al.
AUTOIMMUNITY REVIEWS (2013)
The PD-1/PD-L1 Pathway in Human Pathology
M. Saresella et al.
CURRENT MOLECULAR MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The role of the PD-1 pathway in autoimmunity and peripheral tolerance
Brian T. Fife et al.
YEAR IN IMMUNOLOGY (2011)
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice
W. Joost Lesterhuis et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
The PD-1 pathway in tolerance and autoimmunity
Loise M. Francisco et al.
IMMUNOLOGICAL REVIEWS (2010)
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice
Rupal Ramakrishnan et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Cisplatin and dimethyl sulfoxide react to form an adducted compound with reduced cytotoxicity and neurotoxicity
Stephanie J. Fischer et al.
NEUROTOXICOLOGY (2008)
The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Arlene H. Sharpe et al.
NATURE IMMUNOLOGY (2007)
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells
C Blank et al.
CANCER RESEARCH (2004)
分享论文
